Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)

4.29
Delayed Data
As of Feb 24
 +0.10 / +2.39%
Today’s Change
2.63
Today|||52-Week Range
6.30
+18.51%
Year-to-Date
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
Feb 24 / Zacks.com - Paid Partner Content
Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
Feb 17 / Zacks.com - Paid Partner Content
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
Feb 24 / Zacks.com - Paid Partner Content
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
Feb 16 / Zacks.com - Paid Partner Content
Radius Health (RDUS) Posts Wider Loss in Q4
Feb 24 / Zacks.com - Paid Partner Content
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
Feb 16 / Zacks.com - Paid Partner Content
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
Feb 23 / Zacks.com - Paid Partner Content
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
Feb 16 / Zacks.com - Paid Partner Content
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
Feb 22 / Zacks.com - Paid Partner Content
Prothena (PRTA) Reports Wider-than-Expected Loss in Q4
Feb 15 / Zacks.com - Paid Partner Content
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
Feb 20 / Zacks.com - Paid Partner Content
AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
Feb 15 / Zacks.com - Paid Partner Content
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
Feb 17 / Zacks.com - Paid Partner Content
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
Feb 15 / Zacks.com - Paid Partner Content
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb 17 / Zacks.com - Paid Partner Content